Lilly says new daily pill can help with weight loss, blood sugar
(NewsNation) — Eli Lilly announced Thursday its experimental weight-loss pill passed its first late-stage trial among patients with diabetes, delivering on the company's promise to lower blood sugar and body weight like other GLP-1 drugs such as Ozempic and Wegovy.
Lilly's Phase 3 trial showed that Type 2 diabetes patients lost an average of 16 pounds, or nearly 8% of their body weight, over 40 weeks. When the study ended, weight loss did not plateau, suggesting that patients may continue to lose weight, Lilly said.
The daily pill, called orforglipron, lowered blood sugar levels by an average of 1.3% and has a 'safety profile' consistent with other GLP-1 drugs, according to Lilly.
Man dies after getting wrong treatment, doc disciplined
On Monday, Pfizer ended development of its once-daily weight-loss pill, called danuglipron, after a trial patient experienced a possible drug-induced liver injury that ended once the patient stopped taking the drug.
Lilly said 8% of trial patients on orforglipron's highest dose discontinued treatment due to adverse events.
If the drug is approved, Lilly said it is 'confident in its ability to launch orforglipron worldwide without supply constraints.'
'As a convenient once-daily pill, orforglipron may provide a new option and, if approved, could be readily manufactured and launched at scale for use by people around the world,' said Lilly CEO David A. Ricks.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Lilly partners with Camurus in search of a long-lasting obesity drug
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Looking to defend its giant cardiometabolic health franchise, Eli Lilly is licensing a technology from Swedish biotechnology firm Camurus that promises to produce longer-acting medications. Camurus' FluidCrystal technology is designed to methodically release a therapeutic drug substance into the body over a period of days or months. After an injection, the solution interacts with bodily fluids to transform into a liquid crystalline gel. The gel holds the active ingredient and then slowly degrades, releasing medicine. The deal includes an unspecified upfront payment as part of an initial package that may be worth as much as $290 million, Camurus said Tuesday. That figure also includes payments for reaching certain development and regulatory milestones. Another $580 million could be available for meeting sales goals, along with mid-single digit royalties for successful products. Lilly and rival Novo Nordisk revolutionized diabetes and obesity treatment over the last few years with GLP-1 medicines that opened up one of the biggest markets the pharmaceutical industry has ever seen. In the first quarter alone, Lilly raked in more than $6 billion from sales of tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity. Novo brought in even more from its Ozempic and Wegovy. Now Lilly and Novo are faced with defending the market as a raft of competitors vie to offer newer and better options. Both companies have bulked up their pipelines; Lilly recently claimed success in a Phase 3 trial of a GLP-1 medicine that can be taken in pill form instead of injection. It also has a triple-acting drug in development and a number of other experimental medicines that work differently. The Camurus deal allows Lilly to apply the long-acting technology to as many as four of its drug compounds. That may help the company stave off competitors such as Metsera, which in January announced promising research for its experimental long-acting GLP-1 shot. Meanwhile, Roche recently announced a $1.65 billion deal to expand its obesity pipeline and Amgen and Viking Therapeutics are both moving into late-stage studies of potential rival treatments. Companies are also working on ways to augment the Lilly and Novo medicines. Veru is testing a drug designed to help preserve muscle when taken with Novo's Wegovy. Regeneron and others are conducting similar research. Recommended Reading Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs
New York Post
4 hours ago
- New York Post
Ozempic penis: Male users reveal shocking change to their genitalia after injecting weight-loss shot
It's the miracle drug that promises to shrink your size — except where it matters. Male Ozempic users say their penises have gotten bigger since they started injecting the weight-loss shot, with dozens of well-endowed fellas flocking to online forums to fawn over their expanded members. 'I recently measured myself down there and noticed I gained about one inch,' an anonymous user recently claimed on a Reddit thread. Advertisement 'Now I think people will say it was because of the fat loss. However at the time I measured myself before (4 years ago), I was thinner,' the man claimed. 'I also bone pressed during measurement before and also this time. Has anyone else noticed this change in themselves?' 3 Male Ozempic users say their penises have gotten bigger since they started injecting the weight-loss shot, with dozens of well-endowed fellas flocking to online forums to fawn over their expanded members. Shutterstock / Andrey_Popov 'Yes,' another happy Redditor responded. 'I gained 1.5 inches in length. No joke. Like you I obviously know how long I was before I got very fat. Then after about seven months on Tirzepatide in my case I gained 1.5 inches in length. Definitely not all from weight loss.' Advertisement 'I noticed that happen to me as well,' a third man remarked. 'Yeah, wife has definitely noticed a difference, was 278lbs down to under 200 lbs,' an additional commenter claimed. Meanwhile, other men also claimed that they had noticed a size difference after taking Ozempic, but put it down to better blood flow and reduced fat around the pubic area. Advertisement Another Redditor responded saying the size difference was likely due to different external conditions during the before and after measurements. 'I feel like nobody is really reading what you are writing, that they blame the weight loss while you measured the first time when you were actually lighter,' the explained. 'Ozempic does not enlarge your penis, but an erect penis may change size considerably depending on time of day, temperature, and factors other than sexual arousal. So it's probably just simply that.' 3 Some men also admitted that they had noticed a size difference after taking Ozempic, but put it down to better blood flow and reduced fat around the pubic area. myskin – Advertisement 3 Since it became widely available across America in 2024, users have reported an array of unexpected side effects. K KStock – The phenonemon — dubbed 'Ozempic penis' or 'Ozemd**k' — is just the latest in a series of side effects users of the weight-loss drugs have allegedly experencied. 'Ozempic mouth' is another recently reported side effect, marked by pronounced folds at the corners of the mouth, noticeable wrinkles on the lips, and sagging skin along the lip contours and chin area Those alarmed by their changed appearance are now turning to cosmetic treatments – such as dermal fillers – to restore lost volume around the mouth area.
New York Post
5 hours ago
- New York Post
Weight loss drugs like Ozempic could mess with your birth control — and get you pregnant
A UK watchdog is urging women on GLP-1 weight-loss drugs like Ozempic and Mounjaro to use effective forms of birth control after receiving more than 40 pregnancy-related reports linked to the medications. The warning comes as women flood social media with stories of their so-called 'Ozempic babies' — including surprise pregnancies while on the pill. Trying to shed pounds, not grow a baby bump? Here's what you need to know about GLP-1s, pregnancy and the best contraception options to stay protected. 4 Studies show that at least one in eight US adults have tried GLP-1s. íÅí°íâ¬í¸í½í° íâíµí¼íµíËí°í¾ – What's in your GLP-1? Several GLP-1 drugs dominate the market, including Ozempic and Wegovy. Both contain semaglutide, an active ingredient that mimics a natural hormone in the body that boosts insulin production, slows digestion and curbs appetite. Then there's Saxenda and Victoza, powered by liraglutide, which functions in a similar way. Newer drugs like Mounjaro and Zepbound rely on tirzepatide, a key ingredient that targets a second hormone involved in appetite and blood sugar control. A surprise side effect While gastrointestinal symptoms like nausea, vomiting and diarrhea are common with GLP-1s, the surprise side effect making waves is unexpected pregnancy. The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has received 28 reports related to pregnancy in patients on tirzepatide, and nine each for semaglutide and liraglutide. 4 Women on tirzepatide-based GLP-1s should use barrier contraception. nenetus – In an alert this week, the agency warned that tirzepatide may reduce the effectiveness of oral contraceptives, especially in women with higher body weight. As a result, it recommended using barrier methods like condoms while on drugs like Mounjaro. So far, there's no evidence that GLP-1s affect non-oral birth control like IUDs, implants, patches, or rings, according to the UK's Faculty of Reproductive Healthcare. And yes, the advice applies even to women previously told they were infertile. GLP-1s have been shown to boost fertility by aiding weight loss, reducing inflammation and improving insulin sensitivity — leading some to conceive just months after starting treatment. 4 GLP-1 agonists can increase your fertility, but they can also interfere with pregnancy. Louis-Photo – Can you take GLP-1s while pregnant? Experts say no — at least not yet. There's not enough data to confirm whether GLP-1s are safe during pregnancy. While a some human studies suggests there is no harm in first-trimester use, testing in animals has shown the drugs could increase the risk of miscarriage and birth defects. 4 Scientists are still working to understand whether GLP-1s can negatively impact a developing fetus. Evrymmnt – Another reason to skip GLP-1s while pregnant: they suppress your appetite and can trigger gastrointestinal issues, which may lead to nutrient deficiencies that impact fetal development. The drugs should also be avoided during breastfeeding, since there's not enough research to confirm safety for infants. Trying to conceive? Here's the timeline If you're planning to get pregnant, the MHRA recommended stopping GLP-1s before you start trying to conceive and giving your body time to clear the drugs. For semaglutide users, that means quitting at least two months ahead. If you're on tirzepatide, stop one month before trying. Liraglutide clears the system faster, so you can stop right before you start trying to conceive.
